APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for PrEP

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Drugs for PrEP Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173986460328 December 2025194 pages

Choose your research edition.

Industry ResearchDrugs for PrEP Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for PrEP Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Drugs for PrEP Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for PrEP Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for PrEP Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Drugs for PrEP market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for PrEP include Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, North China Pharmaceutical, Chengdu Brilliant Pharmaceutical, Anhui Baker Biopharmaceutical, Zydus, ViiV Healthcare, Teva and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for PrEP market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for PrEP and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for PrEP sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for PrEP market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for PrEP Segment by Company

Chia Tai Tianqing Pharmaceutical

Qilu Pharmaceutical

North China Pharmaceutical

Chengdu Brilliant Pharmaceutical

Anhui Baker Biopharmaceutical

Zydus

ViiV Healthcare

Teva

Mylan

Gilead Sciences

Aurobindo Pharma

Amneal Pharmaceuticals

Drugs for PrEP Segment by Type

Oral Drugs

Injections

Drugs for PrEP Segment by Application

Hospital and Clinic

Pharmacy

Other

Drugs for PrEP Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for PrEP market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for PrEP and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for PrEP.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for PrEP market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for PrEP manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Drugs for PrEP in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Drugs for PrEP in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Drugs for PrEP Industry Trends Table 2. Drugs for PrEP Industry Drivers Table 3. Drugs for PrEP Industry Opportunities and Challenges Table 4. Drugs for PrEP Industry Restraints Table 5. Global Drugs for PrEP Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Drugs for PrEP Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Drugs for PrEP Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Drugs for PrEP Sales Market Share by Manufacturers Table 9. Global Drugs for PrEP Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Drugs for PrEP Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Drugs for PrEP Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Drugs for PrEP Manufacturers, Product Type & Application Table 13. Global Drugs for PrEP Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for PrEP by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Drugs Table 17. Major Manufacturers of Injections Table 18. Global Drugs for PrEP Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 20. Global Drugs for PrEP Sales by Type (2027-2032) & (K Units) Table 21. Global Drugs for PrEP Sales Market Share by Type (2021-2026) Table 22. Global Drugs for PrEP Sales Market Share by Type (2027-2032) Table 23. Global Drugs for PrEP Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Drugs for PrEP Revenue by Type (2021-2026) & (K Units) Table 25. Global Drugs for PrEP Revenue by Type (2027-2032) & (K Units) Table 26. Global Drugs for PrEP Revenue Market Share by Type (2021-2026) Table 27. Global Drugs for PrEP Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital and Clinic Table 29. Major Manufacturers of Pharmacy Table 30. Major Manufacturers of Other Table 31. Global Drugs for PrEP Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 33. Global Drugs for PrEP Sales by Application (2027-2032) & (K Units) Table 34. Global Drugs for PrEP Sales Market Share by Application (2021-2026) Table 35. Global Drugs for PrEP Sales Market Share by Application (2027-2032) Table 36. Global Drugs for PrEP Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Drugs for PrEP Revenue by Application (2021-2026) & (K Units) Table 38. Global Drugs for PrEP Revenue by Application (2027-2032) & (K Units) Table 39. Global Drugs for PrEP Revenue Market Share by Application (2021-2026) Table 40. Global Drugs for PrEP Revenue Market Share by Application (2027-2032) Table 41. Global Drugs for PrEP Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Drugs for PrEP Sales by Region (2021-2026) & (K Units) Table 43. Global Drugs for PrEP Sales Market Share by Region (2021-2026) Table 44. Global Drugs for PrEP Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Drugs for PrEP Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Drugs for PrEP Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 48. North America Drugs for PrEP Sales by Country (2027-2032) & (K Units) Table 49. Europe Drugs for PrEP Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 51. Europe Drugs for PrEP Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Drugs for PrEP Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Drugs for PrEP Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Drugs for PrEP Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Drugs for PrEP Sales by Country (2027-2032) & (K Units) Table 58. Global Drugs for PrEP Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Drugs for PrEP Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Drugs for PrEP Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Drugs for PrEP Revenue Market Share by Region (2021-2026) Table 62. Global Drugs for PrEP Revenue Market Share by Region (2027-2032) Table 63. Chia Tai Tianqing Pharmaceutical Company Information Table 64. Chia Tai Tianqing Pharmaceutical Business Overview Table 65. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio Table 67. Chia Tai Tianqing Pharmaceutical Recent Development Table 68. Qilu Pharmaceutical Company Information Table 69. Qilu Pharmaceutical Business Overview Table 70. Qilu Pharmaceutical Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Qilu Pharmaceutical Drugs for PrEP Product Portfolio Table 72. Qilu Pharmaceutical Recent Development Table 73. North China Pharmaceutical Company Information Table 74. North China Pharmaceutical Business Overview Table 75. North China Pharmaceutical Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. North China Pharmaceutical Drugs for PrEP Product Portfolio Table 77. North China Pharmaceutical Recent Development Table 78. Chengdu Brilliant Pharmaceutical Company Information Table 79. Chengdu Brilliant Pharmaceutical Business Overview Table 80. Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio Table 82. Chengdu Brilliant Pharmaceutical Recent Development Table 83. Anhui Baker Biopharmaceutical Company Information Table 84. Anhui Baker Biopharmaceutical Business Overview Table 85. Anhui Baker Biopharmaceutical Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio Table 87. Anhui Baker Biopharmaceutical Recent Development Table 88. Zydus Company Information Table 89. Zydus Business Overview Table 90. Zydus Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Zydus Drugs for PrEP Product Portfolio Table 92. Zydus Recent Development Table 93. ViiV Healthcare Company Information Table 94. ViiV Healthcare Business Overview Table 95. ViiV Healthcare Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. ViiV Healthcare Drugs for PrEP Product Portfolio Table 97. ViiV Healthcare Recent Development Table 98. Teva Company Information Table 99. Teva Business Overview Table 100. Teva Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Teva Drugs for PrEP Product Portfolio Table 102. Teva Recent Development Table 103. Mylan Company Information Table 104. Mylan Business Overview Table 105. Mylan Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Mylan Drugs for PrEP Product Portfolio Table 107. Mylan Recent Development Table 108. Gilead Sciences Company Information Table 109. Gilead Sciences Business Overview Table 110. Gilead Sciences Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Gilead Sciences Drugs for PrEP Product Portfolio Table 112. Gilead Sciences Recent Development Table 113. Aurobindo Pharma Company Information Table 114. Aurobindo Pharma Business Overview Table 115. Aurobindo Pharma Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Aurobindo Pharma Drugs for PrEP Product Portfolio Table 117. Aurobindo Pharma Recent Development Table 118. Amneal Pharmaceuticals Company Information Table 119. Amneal Pharmaceuticals Business Overview Table 120. Amneal Pharmaceuticals Drugs for PrEP Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Amneal Pharmaceuticals Drugs for PrEP Product Portfolio Table 122. Amneal Pharmaceuticals Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Drugs for PrEP Distributors List Table 126. Drugs for PrEP Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Drugs for PrEP Product Image Figure 2. Global Drugs for PrEP Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for PrEP Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for PrEP Sales (2021-2032) & (K Units) Figure 5. Global Drugs for PrEP Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Drugs for PrEP Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Drugs Image Figure 9. Injections Image Figure 10. Global Drugs for PrEP Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Drugs for PrEP Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs for PrEP Sales Market Share by Type (2021-2032) Figure 13. Global Drugs for PrEP Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Drugs for PrEP Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Drugs for PrEP Revenue Market Share by Type (2021-2032) Figure 16. Hospital and Clinic Image Figure 17. Pharmacy Image Figure 18. Other Image Figure 19. Global Drugs for PrEP Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Drugs for PrEP Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Drugs for PrEP Sales Market Share by Application (2021-2032) Figure 22. Global Drugs for PrEP Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Drugs for PrEP Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Drugs for PrEP Revenue Market Share by Application (2021-2032) Figure 25. North America Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Drugs for PrEP Sales Market Share by Country (2021-2032) Figure 27. U.S. Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Drugs for PrEP Sales Market Share by Country (2021-2032) Figure 32. Germany Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Drugs for PrEP Sales Market Share by Country (2021-2032) Figure 39. China Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Drugs for PrEP Sales Market Share by Country (2021-2032) Figure 47. Brazil Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Drugs for PrEP Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Drugs for PrEP Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Drugs for PrEP Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Drugs for PrEP Revenue (2021-2032) & (US$ Million) Figure 58. North America Drugs for PrEP Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Drugs for PrEP Revenue (2021-2032) & (US$ Million) Figure 60. Europe Drugs for PrEP Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Drugs for PrEP Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Drugs for PrEP Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Drugs for PrEP Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Drugs for PrEP Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Drugs for PrEP Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Drugs for PrEP Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Qilu Pharmaceutical
  • North China Pharmaceutical
  • Chengdu Brilliant Pharmaceutical
  • Anhui Baker Biopharmaceutical
  • Zydus
  • ViiV Healthcare
  • Teva
  • Mylan
  • Gilead Sciences
  • Aurobindo Pharma
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for PrEP Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for PrEP Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Drugs for PrEP Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Drugs for PrEP Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Drugs for PrEP Market Dynamics
  1. 2.1 Drugs for PrEP Industry Trends
  2. 2.2 Drugs for PrEP Industry Drivers
  3. 2.3 Drugs for PrEP Industry Opportunities and Challenges
  4. 2.4 Drugs for PrEP Industry Restraints
3 Drugs for PrEP Market by Manufacturers
  1. 3.1 Global Drugs for PrEP Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Drugs for PrEP Sales by Manufacturers (2021-2026)
  3. 3.3 Global Drugs for PrEP Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Drugs for PrEP Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for PrEP Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Drugs for PrEP Manufacturers, Product Type & Application
  7. 3.7 Global Drugs for PrEP Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for PrEP Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for PrEP Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for PrEP Tier 1, Tier 2, and Tier 3
4 Drugs for PrEP Market by Type
  1. 4.1 Drugs for PrEP Type Introduction
  2. 4.1.1 Oral Drugs
  3. 4.1.2 Injections
  4. 4.2 Global Drugs for PrEP Sales by Type
  5. 4.2.1 Global Drugs for PrEP Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drugs for PrEP Sales by Type (2021-2032)
  7. 4.2.3 Global Drugs for PrEP Sales Market Share by Type (2021-2032)
  8. 4.3 Global Drugs for PrEP Revenue by Type
  9. 4.3.1 Global Drugs for PrEP Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Drugs for PrEP Revenue by Type (2021-2032)
  11. 4.3.3 Global Drugs for PrEP Revenue Market Share by Type (2021-2032)
5 Drugs for PrEP Market by Application
  1. 5.1 Drugs for PrEP Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Drugs for PrEP Sales by Application
  6. 5.2.1 Global Drugs for PrEP Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for PrEP Sales by Application (2021-2032)
  8. 5.2.3 Global Drugs for PrEP Sales Market Share by Application (2021-2032)
  9. 5.3 Global Drugs for PrEP Revenue by Application
  10. 5.3.1 Global Drugs for PrEP Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Drugs for PrEP Revenue by Application (2021-2032)
  12. 5.3.3 Global Drugs for PrEP Revenue Market Share by Application (2021-2032)
6 Global Drugs for PrEP Sales by Region
  1. 6.1 Global Drugs for PrEP Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for PrEP Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for PrEP Sales by Region (2021-2026)
  4. 6.2.2 Global Drugs for PrEP Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for PrEP Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Drugs for PrEP Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Drugs for PrEP Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Drugs for PrEP Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Drugs for PrEP Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Drugs for PrEP Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Drugs for PrEP Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Drugs for PrEP Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Drugs for PrEP Revenue by Region
  1. 7.1 Global Drugs for PrEP Revenue by Region
  2. 7.1.1 Global Drugs for PrEP Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Drugs for PrEP Revenue by Region (2021-2026)
  4. 7.1.3 Global Drugs for PrEP Revenue by Region (2027-2032)
  5. 7.1.4 Global Drugs for PrEP Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Drugs for PrEP Revenue (2021-2032)
  8. 7.2.2 North America Drugs for PrEP Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Drugs for PrEP Revenue (2021-2032)
  11. 7.3.2 Europe Drugs for PrEP Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Drugs for PrEP Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Drugs for PrEP Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Drugs for PrEP Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Drugs for PrEP Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Qilu Pharmaceutical
  8. 8.2.1 Qilu Pharmaceutical Company Information
  9. 8.2.2 Qilu Pharmaceutical Business Overview
  10. 8.2.3 Qilu Pharmaceutical Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Qilu Pharmaceutical Drugs for PrEP Product Portfolio
  12. 8.2.5 Qilu Pharmaceutical Recent Developments
  13. 8.3 North China Pharmaceutical
  14. 8.3.1 North China Pharmaceutical Company Information
  15. 8.3.2 North China Pharmaceutical Business Overview
  16. 8.3.3 North China Pharmaceutical Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 North China Pharmaceutical Drugs for PrEP Product Portfolio
  18. 8.3.5 North China Pharmaceutical Recent Developments
  19. 8.4 Chengdu Brilliant Pharmaceutical
  20. 8.4.1 Chengdu Brilliant Pharmaceutical Company Information
  21. 8.4.2 Chengdu Brilliant Pharmaceutical Business Overview
  22. 8.4.3 Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio
  24. 8.4.5 Chengdu Brilliant Pharmaceutical Recent Developments
  25. 8.5 Anhui Baker Biopharmaceutical
  26. 8.5.1 Anhui Baker Biopharmaceutical Company Information
  27. 8.5.2 Anhui Baker Biopharmaceutical Business Overview
  28. 8.5.3 Anhui Baker Biopharmaceutical Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio
  30. 8.5.5 Anhui Baker Biopharmaceutical Recent Developments
  31. 8.6 Zydus
  32. 8.6.1 Zydus Company Information
  33. 8.6.2 Zydus Business Overview
  34. 8.6.3 Zydus Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Zydus Drugs for PrEP Product Portfolio
  36. 8.6.5 Zydus Recent Developments
  37. 8.7 ViiV Healthcare
  38. 8.7.1 ViiV Healthcare Company Information
  39. 8.7.2 ViiV Healthcare Business Overview
  40. 8.7.3 ViiV Healthcare Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ViiV Healthcare Drugs for PrEP Product Portfolio
  42. 8.7.5 ViiV Healthcare Recent Developments
  43. 8.8 Teva
  44. 8.8.1 Teva Company Information
  45. 8.8.2 Teva Business Overview
  46. 8.8.3 Teva Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teva Drugs for PrEP Product Portfolio
  48. 8.8.5 Teva Recent Developments
  49. 8.9 Mylan
  50. 8.9.1 Mylan Company Information
  51. 8.9.2 Mylan Business Overview
  52. 8.9.3 Mylan Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mylan Drugs for PrEP Product Portfolio
  54. 8.9.5 Mylan Recent Developments
  55. 8.10 Gilead Sciences
  56. 8.10.1 Gilead Sciences Company Information
  57. 8.10.2 Gilead Sciences Business Overview
  58. 8.10.3 Gilead Sciences Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Gilead Sciences Drugs for PrEP Product Portfolio
  60. 8.10.5 Gilead Sciences Recent Developments
  61. 8.11 Aurobindo Pharma
  62. 8.11.1 Aurobindo Pharma Company Information
  63. 8.11.2 Aurobindo Pharma Business Overview
  64. 8.11.3 Aurobindo Pharma Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Aurobindo Pharma Drugs for PrEP Product Portfolio
  66. 8.11.5 Aurobindo Pharma Recent Developments
  67. 8.12 Amneal Pharmaceuticals
  68. 8.12.1 Amneal Pharmaceuticals Company Information
  69. 8.12.2 Amneal Pharmaceuticals Business Overview
  70. 8.12.3 Amneal Pharmaceuticals Drugs for PrEP Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amneal Pharmaceuticals Drugs for PrEP Product Portfolio
  72. 8.12.5 Amneal Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for PrEP Value Chain Analysis
  2. 9.1.1 Drugs for PrEP Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for PrEP Production Mode & Process
  6. 9.2 Drugs for PrEP Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for PrEP Distributors
  9. 9.2.3 Drugs for PrEP Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst